Juno Therapeutics, the biotechnology startup launched in December by leading cancer scientists here and in New York, has tacked another $30 million on to its bankroll.

The Seattle company said its funding round has been completed at $176 million, up from about $145 million in January. Its backers include ARCH Venture Partners, the Alaska Permanent Fund, the personal investment company of Jeff Bezos, and Venrock.

CEO Hans Bishop said the financing “provides significant resources to support truly transformative science.”